naratriptan has been researched along with Atrophic Muscular Disorders in 2 studies
naratriptan: structure given in first source
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Minamiyama, M | 1 |
| Katsuno, M | 1 |
| Adachi, H | 1 |
| Doi, H | 1 |
| Kondo, N | 1 |
| Iida, M | 1 |
| Ishigaki, S | 1 |
| Fujioka, Y | 1 |
| Matsumoto, S | 1 |
| Miyazaki, Y | 1 |
| Tanaka, F | 1 |
| Kurihara, H | 1 |
| Sobue, G | 1 |
| Merry, DE | 1 |
2 other studies available for naratriptan and Atrophic Muscular Disorders
| Article | Year |
|---|---|
Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract.
Topics: Animals; Calcitonin; Calcitonin Gene-Related Peptide; Cell Survival; Cells, Cultured; Dual Specifici | 2012 |
Attacking the flank: targeting new pathways in SBMA.
Topics: Animals; Calcitonin; Male; Muscular Disorders, Atrophic; Peptides; Piperidines; Protein Precursors; | 2012 |